Acorda Therapeutics' CVT-301, a drug used in treating people with Parkinson’s disease, showed significant improvement in motor functions during a Phase 3 clinical trial.
“We are greatly encourage by the efficacy
and safety results of this trial, which validate the positive reults,” Acorda Chief Medical Officer Burkhar Blank said in a press release. “We would like to express our gratitude to
the study volunteers and clinical investigators who participated in this trial
to advance our understanding of this potentially important therapy for people
with Parkinson’s.”
Acorda's new Parkinson's disease drug shows improved results
Alerts Sign-up